Why did Thermo Electron swing from a $182 million profit to a $175 million net loss?

The swing came from several non-operating or one-time items. Continuing operations posted $149.6 million of restructuring and unusual costs, mainly at Thermo Ecotek's power plants and Measurement and Control units being sold. The company also recorded a $50 million provision for the estimated loss on disposing discontinued businesses, which includes a $174 million tax charge, and $111.5 million of losses from discontinued operations. Gains on subsidiary stock issuances that boosted 1998 earnings ($18.6 million) were absent in 1999.

What is the reorganization, and how could it affect shareholders?

The reorganization would leave Thermo Electron focused on measurement and detection instruments. Shareholders would receive shares of spun-off Thermo Fibertek and a medical products company as a dividend. Most remaining majority-owned public subsidiaries would be taken private through tender offers, short-form mergers, or exchange offers at set exchange ratios, and non-core businesses would be sold for roughly $1 billion. Completion depends on IRS tax rulings, SEC reviews, minority shareholder acceptances reaching 90% ownership, and other conditions, so timing and outcomes are uncertain.

Does Thermo Electron pay dividends, and how much cash does it have?

No. The company has never paid cash dividends and does not expect to in the foreseeable future, prioritizing reinvestment. It held $877.4 million in cash and short- and long-term investments at year-end 1999, but $852.7 million of that was held by majority-owned subsidiaries, and the company notes that accessing it may be limited by fiduciary duties to minority shareholders and tax considerations.

Which segments drove growth, and which underperformed?

Measurement and Control grew sales 44% to $747.3 million, largely through acquisitions, though its segment income margin fell to 6.5% from 9.8%, and it is divesting its power electronics business. Optical Technologies rose 18% to $802.0 million, but margins declined to 10.6% after including Spectra-Physics. Life Sciences grew 8% to $762.8 million with a stable margin near 15%. Power Generation saw a segment loss of $82.9 million (pretax) due to contract expirations and write-downs, and its outlook is weaker as avoided-cost rates are expected to persist.

What are the key risks highlighted in the filing?

Key risks include the complexity and uncertain completion of the reorganization; the ability to integrate acquisitions and realize about $1.2 billion of goodwill (cost in excess of net assets); international exposure, with about 63% of continuing revenue from outside the company's home market and exposure to Asian economic instability and currency swings; dependence on capital spending cycles in semiconductors, process control, and oil and gas; and litigation, including patent cases involving Finnigan and a Rhode Island judgment of about $21 million that the company is contesting.

TMO 10-K FY2000 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed March 22, 2000. Cited figures are marked; the original filing is the authoritative source.

Thermo Electron Corporation's fiscal 1999 10-K (year ended January 1, 2000) reports a year of sharp contrast: continuing-operations revenue rose 20% to $2.47 billion^a, driven largely by acquisitions such as Spectra-Physics, but the company posted a net loss of $174.6 million ($1.13 per diluted share).

The loss was driven by $149.6 million^b of restructuring and other unusual costs in continuing operations, a $50 million provision for loss on disposal of discontinued operations (including a $174 million tax provision), and a $111.5 million loss from discontinued operations. Operating income fell to $99.0 million from $233.7 million, and the effective tax rate reached 88%. Continuing operations' segment income declined, with Power Generation (Thermo Ecotek) the most affected after fixed-rate California power contracts expired and the company wrote down its coal-beneficiation plant and Delano facilities.

The filing's main story is a major reorganization announced January 31, 2000. Thermo Electron plans to refocus solely on measurement and detection instruments, spin off Thermo Fibertek and a medical products company as dividends, sell non-core businesses with aggregate revenues above $1 billion^c (expected proceeds of about $1 billion in 2000), and take private most of its remaining majority-owned public subsidiaries, which carries an estimated cash outlay of roughly $325 million. Management expects these steps to simplify the structure and free capital for internal growth in life sciences and telecommunications-linked instrumentation.

Investors should weigh the execution risk: many transactions depend on IRS rulings, SEC reviews, 90% ownership thresholds, and asset sale timing. Balance sheet strength remains substantial, with $877.4 million^d in cash and investments (most held by majority-owned subsidiaries), working capital of $1.45 billion, and long-term obligations of $1.57 billion, largely convertible debentures. Notably, the company has never paid cash dividends and does not expect to do so, and a significant portion of its cash is not freely accessible to the parent because it sits in majority-owned subsidiaries.

02—Key points

Key Highlights

Revenue from continuing operations rose 20% to $2.47 billion (from $2.06 billion), with Measurement and Control up 44% and Optical Technologies up 18%, largely from acquisitions including Spectra-Physics.
Net loss of $174.6 million, or $(1.13) per diluted share, versus net income of $181.9 million in 1998, reflecting restructuring charges, a $50 million loss-on-disposal provision (including a $174 million tax provision), and discontinued-operations losses.
Operating income fell to $99.0 million from $233.7 million, with $149.6 million of restructuring and unusual costs in continuing operations, concentrated in Power Generation ($112.2 million) and Measurement and Control ($30.2 million).
Major reorganization: focus on measurement and detection instruments, spin-offs of Thermo Fibertek and a medical products company, sale of non-core businesses (over $1 billion in revenue, approximately $1 billion expected in proceeds in 2000), and take-private of most public subsidiaries.
Power Generation (Thermo Ecotek) weakened as fixed-price California power contracts expired and PG&E moved to lower avoided-cost rates; the company abandoned its Gillette, Wyoming coal-beneficiation plant and wrote down Delano assets.
Liquidity remains solid: $877.4 million of cash and investments, $1.45 billion working capital, and $1.57 billion of long-term obligations, mostly subordinated convertible debentures. Approximately $852.7 million of the liquid assets sits in majority-owned subsidiaries.
Research and development spending rose to $171.1 million (from $128.0 million), and the company describes the 2000 strategy as internal growth plus complementary acquisitions. No cash dividends have ever been paid.

03—Questions

Frequently Asked Questions

Why did Thermo Electron swing from a $182 million profit to a $175 million net loss?
The swing came from several non-operating or one-time items. Continuing operations posted $149.6 million of restructuring and unusual costs, mainly at Thermo Ecotek's power plants and Measurement and Control units being sold. The company also recorded a $50 million provision for the estimated loss on disposing discontinued businesses, which includes a $174 million tax charge, and $111.5 million of losses from discontinued operations. Gains on subsidiary stock issuances that boosted 1998 earnings ($18.6 million) were absent in 1999.
What is the reorganization, and how could it affect shareholders?
The reorganization would leave Thermo Electron focused on measurement and detection instruments. Shareholders would receive shares of spun-off Thermo Fibertek and a medical products company as a dividend. Most remaining majority-owned public subsidiaries would be taken private through tender offers, short-form mergers, or exchange offers at set exchange ratios, and non-core businesses would be sold for roughly $1 billion. Completion depends on IRS tax rulings, SEC reviews, minority shareholder acceptances reaching 90% ownership, and other conditions, so timing and outcomes are uncertain.
Does Thermo Electron pay dividends, and how much cash does it have?
No. The company has never paid cash dividends and does not expect to in the foreseeable future, prioritizing reinvestment. It held $877.4 million in cash and short- and long-term investments at year-end 1999, but $852.7 million of that was held by majority-owned subsidiaries, and the company notes that accessing it may be limited by fiduciary duties to minority shareholders and tax considerations.
Which segments drove growth, and which underperformed?
Measurement and Control grew sales 44% to $747.3 million, largely through acquisitions, though its segment income margin fell to 6.5% from 9.8%, and it is divesting its power electronics business. Optical Technologies rose 18% to $802.0 million, but margins declined to 10.6% after including Spectra-Physics. Life Sciences grew 8% to $762.8 million with a stable margin near 15%. Power Generation saw a segment loss of $82.9 million (pretax) due to contract expirations and write-downs, and its outlook is weaker as avoided-cost rates are expected to persist.
What are the key risks highlighted in the filing?
Key risks include the complexity and uncertain completion of the reorganization; the ability to integrate acquisitions and realize about $1.2 billion of goodwill (cost in excess of net assets); international exposure, with about 63% of continuing revenue from outside the company's home market and exposure to Asian economic instability and currency swings; dependence on capital spending cycles in semiconductors, process control, and oil and gas; and litigation, including patent cases involving Finnigan and a Rhode Island judgment of about $21 million that the company is contesting.

04—Continue

← View all 10-K filings